- IXICO's strong performance in the year ended 30 September has continued, shareholders at the annual general meeting today will be told.

Chairman Dr Andrew Richards will say: "The delivery of existing contracted revenues together with our recently announced contracts in Alzheimer's disease and Huntington's disease remain an important part of our operational focus and investment.

"Our relationships with these pharmaceutical customers allow us to demonstrate the value of our portfolio of digital products and data solutions. Our agreement to develop and pilot Assessa® in the clinical management of Multiple Sclerosis with a pharmaceutical partner is a recent example of progress in executing this strategy. The pilot deployment and planning the subsequent roll out will be a key focus for this coming year.

"We are continuing to showcase our digital healthcare products through pilots and partnerships with the NHS and 3rd sector organisations as a way of building our evidence base and profile. The Optimal Medicine products, team, customers and US base are now part of the enlarged group, adding breadth to our brain health capabilities in real world data collection and clinical decision support."

The company also announced that Charles Spicer has stepped down as an executive director with immediate effect but will remain on the board as a Non-Executive Director. He has been involved with IXICO since 2011, first as an adviser on corporate strategy and subsequently joined the Board in July 2013. He played a key role in the reverse takeover of Phytopharm plc in October 2013 and more recently, the acquisition of Optimal Medicine Limited. Charles' experience as a director and adviser in the medtech and life sciences sectors has been particularly invaluable as IXICO transitioned from a private company to a plc. In his role as a Non-Executive Director he will continue to support the Company's corporate development plans.

Story provided by